嵌合抗原受体
CD19
自然杀伤性T细胞
自然杀伤细胞
淋巴因子激活杀伤细胞
细胞
癌症研究
抗原
细胞毒性T细胞
免疫疗法
免疫学
白细胞介素21
T细胞
生物
免疫系统
体外
遗传学
作者
Enli Liu,David Marín,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Başar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu
标识
DOI：10.1056/nejmoa1910607
摘要
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
GingerF
小邸
lgq12697
馆长
坦率白萱
Virtual
vizi
丁浩伦
从容芮
wwc
相约在天边
华仔
务实的眼睛
VDC
Dean
Shuo
Wells
404NotFOUND
syvshc
皖公网安备34019202002308
